logo BDSP

Base documentaire

  1. Estimates of the cost-effectiveness of a single course of interferon-alpha2b in patients with histologically mild chronic hepatitis C.

    Article - En anglais


    Chronic hepatitis C is a major cause of illness and death in the United States.

    Interferon-alpha2b can induce clinical, biochemical, and virologic remission in some patients with chronic hepatitis C, but the long-term cost-effectiveness of this treatment, particularly in patients with histologically mild disease, is unknown.


    To estimate the cost-effectiveness of interferon-a2b in mild chronic hepatitis C. Design : Meta-analysis of five prospective trials and cost-effectiveness analysis.

    Projection of the clinical and economic outcomes expected from loss of hepatitis C virus was done by using a Markov simulation.

    The potential effect of uncertainty in the model assumptions was tested by using sensitivity analyses.

    Data Sources 

    Search of the MEDLINE database, opinions of expert panels, hospital cost data, and adjusted physician charges.


    Hypothetical cohorts with histologically mild chronic hepatitis C. Intervention : The model assumed a single 6-month course of recombinant interferon-alpha2b.


    Life expectancy, quality-adjusted life expectancy, costs, and marginal cost-effectiveness ratios from a managed care perspective.


    In 27% of patients with mild chronic hepatitis C treated with interferon-alpha2b for 6 months, serum alanine aminotransferase levels permanently returned to normal and viral status remained negative. (...)

    Mots-clés Pascal : Hépatite virale C, Virose, Infection, Epidémiologie, Etude cohorte, Interféron alpha, Evaluation, Coût, Histopathologie, Efficacité traitement, Etude comparative, Qualité vie, Homme, Etats Unis, Amérique du Nord, Amérique, Appareil digestif pathologie, Foie pathologie, Cytokine, Traitement instrumental, Economie santé

    Mots-clés Pascal anglais : Viral hepatitis C, Viral disease, Infection, Epidemiology, Cohort study, Alpha interferon, Evaluation, Costs, Histopathology, Treatment efficiency, Comparative study, Quality of life, Human, United States, North America, America, Digestive diseases, Hepatic disease, Cytokine, Instrumentation therapy, Health economy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0043411

    Code Inist : 002B05C02G. Création : 17/04/1998.